Navigation Links
Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
Date:3/13/2009

NEW YORK, March 13 /PRNewswire/ -- Jina Ventures is pleased to announce the acquisition of clinical pharmacology and research company, Swiss Pharma Contract (SPC) by leading contract research organization, Covance Inc (NYSE: CVD). Jina Ventures was the exclusive financial advisor to SPC in the transaction, which provides Covance with the facilities and services of Basel, Switzerland area-based SPC.

"We are thrilled to have been an integral part of a deal that we believe adds real value to a well-established global player," said Ron Shah, Managing Partner, Jina Ventures. "There were bids for SPC from several global clinical research organizations, but Covance presented the most compelling opportunity for strategic long-term growth for SPC."

SPC was seed-funded by Novartis Venture Fund in 1998, and provides Phase I clinical trials to leading pharmaceutical clients and biotechnology companies in Europe, the United States and Asia. SPC's leadership includes Dr. Rolf Pokorny and Dr. Michael Seiberling, two industry veterans in the field of Phase I clinical trials.

Jina Ventures invigorated the M&A process by using a customized global auction, which resulted in interest from 14 leading companies, based in Europe, Asia and the U.S. As worldwide M&A volume has declined over the last 12 months, auctions continue to be an effective way to utilize global competitiveness to drive deal value and strategic fit.

On the heels of this transaction, Jina Ventures is poised for major growth in 2009, targeting the close of a second life sciences M&A transaction by mid-year and the launch of its second fund of US$200 million later this year. Jina's second fund is a cross border private equity fund designed to leverage global competitiveness for its portfolio companies in the US and India.

About Jina Ventures:

Founded in 2003, Jina Ventures is a New York-based private equity and M&A advisory firm. Over the past 6 years, Jina Ventures has grown into a full service private equity practice, with both principal investing and cross-border mergers and acquisitions. In addition to New York City, Jina Ventures also has offices in Mumbai, Tokyo, Bangkok and Singapore. More information can be found at www.jinaventures.com.


'/>"/>
SOURCE Jina Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):